Early antithrombotic therapy and COVID-19: a better clinical course? New evidences from real-life cases

The recent COVID-19 carries potential risk factors for VTE and worse clinical course in some patients has an association with thrombosis. While low molecular weight heparins are under investigation for appropriate dosage, other elements could be useful. We share our experience about two patients with unexpected clinical course. © 2020 Czech Society of Cardiology Z.S. All rights reserved.